Net sales and ARPU declined year-over-year, but gross margins and recurring revenue remained strong. Positive EBITDA was achieved for the first time, with cost control and product development supporting cautious optimism for recovery.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.